Oxazepam is a representative of the benzodiazepine group. Features include the medium-length duration of action, the slower onset and especially the degradation that does not run through the cytochrome P450 system. About 2 - 5% of the German population have a mutation here, which leads to a prolonged duration of action. Even damaged livers change the duration of action minimally. It was launched by Boehringer Ingelheim.
Marius Hang
International Division
Director API Export
The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.
No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.
